Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024

Fulcrum Therapeutics, Inc.

2024-Q2 EPS reported $0.45 revenue$80,000,000

Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.
Cash and securities $273.8M as of June 30, 2024; expected to fund operations into 2027.
Phase 3 REACH trial (losmapimod for FSHD) topline data expected by end of October 2024; 260 patients enrolled.
Collaboration with Sanofi for ex-U.S. losmapimod; $80M upfront received in Q2.
Phase 1b pociredir (SCD) advancing; cohorts at 12 mg and 20 mg once daily planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.